Inflammatory findings on species extrapolations: Humans are definitely no 70-kg mice

Archives of Toxicology

Volumn 87, Issue 4, 2013, Pages 563-567

  Leist, Marcel ^a   Hartung, Thomas ^b  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED C REACTIVE PROTEIN; IMMUNOMODULATING AGENT; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

BRAIN ISCHEMIA; DEGENERATIVE DISEASE; DISEASE MODEL; ENDOTOXEMIA; HEALTH HAZARD; HUMAN; INFECTION; INFLAMMATION; NERVE DEGENERATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEPSIS; SPECIES DIFFERENCE; TOXICITY TESTING; TOXICOKINETICS;

ANIMALS; HUMANS; MICE; MODELS, ANIMAL; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; SPECIES SPECIFICITY; TOXICOLOGY;

ANIMALIA; MUS;

EID: 84876685425     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-013-1038-0     Document Type: Review

References (43)

1. Basketter DA, Clewell H, Kimber I, Rossi A, Blaauboer B, Burrier R, Daneshian M, Eskes C, Goldberg A, Hasiwa N, Hoffmann S, Jaworska J, Knudsen TB, Landsiedel R, Leist M, Locke P, Maxwell G, McKim J, McVey EA, Ouédraogo G, Patlewicz G, Pelkonen O, Roggen E, Rovida C, Ruhdel I, Schwarz M, Schepky A, Schoeters G, Skinner N, Trentz K, Turner M, Vanparys P, Yager J, Zurlo J, Hartung T (2012) A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing-t4 report . ALTEX 29(1):3-91
2. Blaauboer BJ, Boekelheide K, Clewell HJ, Daneshian M, Dingemans MM, Goldberg AM, Heneweer M, Jaworska J, Kramer NI, Leist M, Seibert H, Testai E, Vandebriel RJ, Yager JD, Zurlo J (2012) The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. ALTEX 29(4):411-425
3. Buras JA, Holzmann B, Sitkovsky M (2005) Animal models of sepsis: setting the stage. Nat Rev Drug Discov 4(10):854-865
4. Christaki E, Anyfanti P, Opal SM (2011) Immunomodulatory therapy for sepsis: an update. Expert Rev Anti Infect Ther 9(11):1013-1033
5. De Keyser J, Sulter G, Luiten PG (1999) Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci 22(12):535-540
6. Dirnagl U, Fisher M (2012) REPRINT: international, multicenter randomized preclinical trials in translational stroke research: it is time to act. Stroke 43(6):1453-1454
7. Gladstone DJ, Black SE, Hakim AM (2002) Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33(8):2123-2136
8. Gold LS, Manley NB, Slone TH, Rohrbach L, Garfinkel GB (2005) Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997-1998. Toxicol Sci 85:747-808
9. Hackam DG, Redelmeier DA (2006) Translation of research evidence from animals to humans. JAMA 296(14):1731-1732
10. Hartung T (2008) Food for thought. on animal tests. ALTEX 25:3-9
11. Hartung T (2009) Toxicology for the twenty-first century. Nature 460:208-212
12. Hartung T, Leist M (2008) Food for thought. on the evolution of toxicology and the phasing out of animal testing. ALTEX 25(2):91-102
13. Hartung T, McBride M (2011) Food for Thought. on mapping the human toxome. ALTEX 28(2):83-93
14. Hartung T, Zurlo J (2012) Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare. ALTEX 29(3):251-260
15. Hartung T, van Vliet E, Jaworska J, Bonilla L, Skinner N, Thomas R (2012) Systems toxicology. ALTEX 29(2):119-128
16. Hasiwa N, Bailey J, Clausing P, Daneshian M, Eileraas M, Farkas S, Gyertyán I, Hubrecht R, Kobel W, Krummenacher G, Leist M, Lohi H, Miklósi A, Ohl F, Olejniczak K, Schmitt G, Sinnett-Smith P, Smith D, Wagner K, Yager JD, Zurlo J, Hartung T (2011) Critical evaluation of the use of dogs in biomedical research and testing in Europe. ALTEX 28(4):326-340
17. Hasiwa N, Daneshian M, Bruegger P, Fennrich S, Fleck R, Hochadel A, Hoffmann S, Rivera-Mariani FE, Rockel C, Schindler S, Spreitzer I, Stoppelkamp S, Vysyaraju K, Hartung T. (2013) Evidence for the detection of non-endotoxin pyrogens (NEPs) by the whole blood monocyte activation test. ALTEX 30:(in press)
18. Kent RB, Emanuel JR, Ben Neriah Y, Levenson R, Housman DE (1987) Ouabain resistance conferred by expression of the cDNA for a murine Na +, K + -ATPase alpha subunit. Science 237(4817):901-903
19. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 29;8(6):e1000412
20. Leist M, Hartung T, Nicotera P (2008a) The dawning of a new age of toxicology. ALTEX 25(2):103-114
21. Leist M, Kadereit S, Schildknecht S (2008b) Food for thought. on the real success of 3R approaches. ALTEX 25(1):17-32
22. Leist M, Efremova L, Karreman C (2010) Food for thought. considerations and guidelines for basic test method descriptions in toxicology. ALTEX 27(4):309-317
23. Leist M, Lidbury BA, Yang C, Hayden PJ, Kelm JM, Ringeissen S, Detroyer A, Meunier JR, Rathman JF, Jackson GR Jr, Stolper G, Hasiwa N (2012a) Novel technologies and an overall strategy to allow hazard assessment and risk prediction of chemicals, cosmetics, and drugs with animal-free methods. ALTEX 29(4):373-388
24. Leist M, Hasiwa N, Daneshian M, Hartung T (2012b) Validation and quality control of replacement alternatives - current status and future challenges. Toxicol Res 1:8-22. doi: 10.1039/C2TX20011B
25. Macleod M, van der Worp HB (2010) Animal models of neurological disease: are there any babies in the bathwater? Pract Neurol 10(6):312-314
26. Matthews RAJR (2008) Medical progress depends on animal models - doesn't it? J R Soc Med 101:95-98
27. Musch TI, Carroll RG, Just A, Lane PH, Talman WT (2006) Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. doi: 10.1136/bmj.39048.407928
28. NRC-National Research Council, Committee on Animal Models for Assessing Countermeasures to Bioterrorism Agents (2011). Animal Models for Assessing Countermeasures to Bioterrorism Agents (1-153). Washington, DC, USA: The National Academies Press. http://dels.nationalacademies.org/Report/Animal- Models-Assessing-Countermeasures/13233
29. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW (2006) 1,026 experimental treatments in acute stroke. Ann Neurol 59(3):467-477
30. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32(1):56-67
31. Opal SM, Cross AS (1999) Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 13(2):285-297
32. Rice J (2012) Animal models: not close enough. Nature 484(7393):S9
33. Rittirsch D, Hoesel LM, Ward PA (2007) The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 81:137-143
34. Rossini GP, Hartung T (2012) Food for thought. towards tailored assays for cell-based approaches to toxicity testing. ALTEX 29(4):359-372
35. Savitz SI, Fisher M (2007) Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 61(5):396-402
36. Schlepütz M, Rieg AD, Seehase S, Spillner J, Perez-Bouza A, Braunschweig T, Schroeder T, Bernau M, Lambermont V, Schlumbohm C, Sewald K, Autschbach R, Braun A, Kramer BW, Uhlig S, Martin C (2012) Neurally mediated airway constriction in human and other species: a comparative study using precision-cut lung slices (PCLS). PLoS ONE 7(10):e47344
37. Schmidt M, Raghavan B, Müller V, Vogl T, Fejer G, Tchaptchet S, Keck S, Kalis C, Nielsen PJ, Galanos C, Roth J, Skerra A, Martin SF, Freudenberg MA, Goebeler M (2010) Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol 11(9):814-819
38. Schnerch A, Cerdan C, Bhatia M (2010) Distinguishing between mouse and human pluripotent stem cell regulation: the best laid plans of mice and men. Stem Cells 28(3):419-430
39. Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR (2010) Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol 8(3):e1000344
40. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, López CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG; the Inflammation and Host Response to Injury, Large Scale Collaborative Research Program (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA (PubMed PMID: 23401516)
41. Stebbings R, Findlay L, Edwards C, Eastwood D, Bird C, North D, Mistry Y, Dilger P, Liefooghe E, Cludts I, Fox B, Tarrant G, Robinson J, Meager T, Dolman C, Thorpe SJ, Bristow A, Wadhwa M, Thorpe R, Poole S (2007) "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 179(5):3325-3331
42. van der Worp HB, Macleod MR (2011) Preclinical studies of human disease: time to take methodological quality seriously. J Mol Cell Cardiol 51(4):449-450
43. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, Macleod MR (2010) Can animal models of disease reliably inform human studies? PLoS Med 7(3):e1000245